To date, the FDA has approved five ALK TKIs (crizotinib, ceritinib, alectinib, brigatinib, and lorlatinib) as the first-line and follow-up treatment drugs for patients with ALK+ NSCLC (Pirker and Filipits, 2019). The gene discussed is ALK; the disease is non-small cell lung carcinoma.